Head to Head Review: Scinai Immunotherapeutics (SCNI) versus Its Rivals

Scinai Immunotherapeutics (NASDAQ:SCNIGet Free Report) is one of 281 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Scinai Immunotherapeutics to similar businesses based on the strength of its institutional ownership, risk, earnings, valuation, dividends, analyst recommendations and profitability.

Volatility & Risk

Scinai Immunotherapeutics has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics’ peers have a beta of 0.96, suggesting that their average share price is 4% less volatile than the S&P 500.

Institutional & Insider Ownership

11.8% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 16.5% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Scinai Immunotherapeutics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics 0 0 0 0 N/A
Scinai Immunotherapeutics Competitors 1366 4462 11673 199 2.60

As a group, “Biological products, except diagnostic” companies have a potential upside of 113.15%. Given Scinai Immunotherapeutics’ peers higher probable upside, analysts clearly believe Scinai Immunotherapeutics has less favorable growth aspects than its peers.


This table compares Scinai Immunotherapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scinai Immunotherapeutics N/A N/A -49.31%
Scinai Immunotherapeutics Competitors -4,504.48% -140.69% -47.31%

Valuation & Earnings

This table compares Scinai Immunotherapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Scinai Immunotherapeutics N/A -$5.80 million -0.14
Scinai Immunotherapeutics Competitors $737.25 million $120.67 million -2.52

Scinai Immunotherapeutics’ peers have higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


Scinai Immunotherapeutics peers beat Scinai Immunotherapeutics on 6 of the 10 factors compared.

Scinai Immunotherapeutics Company Profile

(Get Free Report)

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.